Iconovo AB (publ)

Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; ICOone single-dose disposable dry powder inhaler; and ICOone nasal single-dose dry powder inhaler now for nasal use. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius to develop dry powder inhalation product, as well as collaboration with Monash h University to. to develop an inhalable and preventive oxytocin treatment to provide effective protection against cotries. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.